4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

Study Description
Brief Summary:
The intent of this open-label, multicenter expanded access program (EAP) is to provide early access to voxelotor prior to market authorization

Condition or disease Intervention/treatment
Sickle Cell Disease Drug: Voxelotor

Detailed Description:

The purpose of this program is to provide early access to voxelotor for patients with sickle cell disease who have exhausted alternative treatment options and are ineligible for actively-recruiting clinical trials of voxelotor.

This EAP may continue until such time that voxelotor is commercially available or the Sponsor discontinues the voxelotor EAP. Discontinuation may occur earlier if an individual participant or physician or Sponsor Medical Monitor decides to discontinue treatment.

Study Design
Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: An Open-Label, Expanded Access Protocol for Patient With Sickle Cell Disease Who Have No Alternative Treatment Options
Arms and Interventions
Outcome Measures
Eligibility Criteria
Contacts and Locations
Tracking Information
First Submitted Date May 7, 2019
First Posted Date May 9, 2019
Last Update Posted Date December 19, 2019
 
Descriptive Information
Brief Title Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options
Official Title An Open-Label, Expanded Access Protocol for Patient With Sickle Cell Disease Who Have No Alternative Treatment Options
Brief Summary The intent of this open-label, multicenter expanded access program (EAP) is to provide early access to voxelotor prior to market authorization
Detailed Description

The purpose of this program is to provide early access to voxelotor for patients with sickle cell disease who have exhausted alternative treatment options and are ineligible for actively-recruiting clinical trials of voxelotor.

This EAP may continue until such time that voxelotor is commercially available or the Sponsor discontinues the voxelotor EAP. Discontinuation may occur earlier if an individual participant or physician or Sponsor Medical Monitor decides to discontinue treatment.

Study Type Expanded Access
Expanded Access Type Individual Patients
Condition Sickle Cell Disease
Intervention Drug: Voxelotor
Other Name: GBT440
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status Approved for marketing
Eligibility Criteria

Inclusion Criteria

  1. Documented diagnosis of sickle cell disease of any genotype confirmed by laboratory testing during screening
  2. Ineligible or unable to participate in actively recruiting clinical studies of voxelotor
  3. Hemoglobin (Hb) ≤ 10.5 g/dL during screening
  4. No alternative treatment options in the judgment of the treating investigator
  5. Participants, who if female and of child bearing potential, agree to use highly effective methods of contraception from study start to 30 days after the last dose of voxelotor, and who if male, agree to use barrier methods of contraception from study start to 30 days after the last dose of voxelotor
  6. Patient has provided documented informed consent (the informed consent form [ICF] must be reviewed and signed by each participant),or for participants under 18 years of age, signed parental/legal guardian consent and participant assent.

Exclusion Criteria

  1. Female who is breast feeding or pregnant
  2. Hepatic dysfunction characterized by alanine aminotransferase (ALT) >4 × ULN
  3. Patients with clinically significant bacterial, fungal, parasitic, or viral infection which require therapy:

    • Patients with acute bacterial infection requiring antibiotic use should delay screening/enrollment until the course of antibiotic therapy has been completed.
    • Patients with known active hepatitis A, B, or C or who are known to be human immunodeficiency virus (HIV) positive
  4. Renal dialysis
  5. Non-SCD conditions or complications of SCD for which survival beyond 3 months is unlikely, in the opinion of the treating Investigator
  6. Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine (prior cholecystectomy is acceptable)
  7. Participated in another clinical trial of an investigational agent (or medical device) within 30 days or 5 half-lives of date of informed consent, whichever is longer, or is currently participating in another trial of an investigational agent (or medical device)
  8. Medical, psychological, or behavioral conditions, which, in the opinion of the Investigator, may preclude safe participation, interfere with compliance or preclude informed consent

The Sponsor Medical Monitor makes the sole and final enrollment determination for any patient.

Sex/Gender
Sexes Eligible for Study: All
Ages 12 Years and older   (Child, Adult, Older Adult)
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT03943615
Other Study ID Numbers GBT440-037
Responsible Party Global Blood Therapeutics
Study Sponsor Global Blood Therapeutics
Collaborators Not Provided
Investigators
Study Director: Jonathan Sorof, MD Global Blood Therapeutics, Inc.
PRS Account Global Blood Therapeutics
Verification Date December 2019